A Phase 1 interventional study of Trazodone HCl and Trazodone HCl in Healthy, sponsored by Labopharm Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-27.
Sponsored by Labopharm Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to compare the pharmacokinetic profiles of extended-release and immediate-release trazodone formulations
The bioavailability of once-daily trazodone extended-release 300 mg caplets (test product) and trazodone immediate-release 100 mg tablets administered q8h (reference product) will be compared in healthy adult volunteers in a randomized, crossover fashion. Morning doses will be administered after an overnight fast. Blood samples will be collected predose and at pre-defined times over 72 hours following the morning dose. Pharmacokinetic parameters will be analyzed using ANOVA. Comparative bioavailability will be assessed on the basis of the ratio of least-squares means and/or 90% confidence interval criteria.
Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Trazodone HCl
Drug: Trazodone HCl
100 mg immediate-release tablet, dosing q8h
300 mg extended-release caplet, single dose
Also known as: Oleptro
Bioequivalence Based on Cmax
Cmax = Maximum plasma concentration Measured in nanograms per millilitre (ng/mL)
Time frame: 72 hours post-dose
Bioequivalence Based on AUCT
AUCT = Area under the concentration-time curve from 0 to the time of the last quantifiable concentration
Time frame: 72 hours post-dose
Bioequivalence Based on AUC∞
AUC∞ = Area under the concentration-time curve extrapolated to infinity
Time frame: 72 hours post-dose
Time of Maximum Measured Plasma Concentration (Tmax)
Time frame: 72 hours post-dose
Apparent Terminal Elimination Half-Life [T½el]
The elimination half-life (T½el) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.
Time frame: 72 hours post-dose
Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24]
Time frame: 24 hours
| Milestone | Test (Trazodone Contramid® OAD) First | Reference (Trazodone IR (Desyrel®) 100 mg 8-hourly) First |
|---|---|---|
| Started | 12 | 12 |
| Completed | 10 | 11 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Milestone | Test (Trazodone Contramid® OAD) First | Reference (Trazodone IR (Desyrel®) 100 mg 8-hourly) First |
|---|---|---|
| Started | 10 | 11 |
| Completed | 10 | 11 |
| Not completed | 0 | 0 |
| Milestone | Test (Trazodone Contramid® OAD) First | Reference (Trazodone IR (Desyrel®) 100 mg 8-hourly) First |
|---|---|---|
| Started | 10 | 11 |
| Completed | 9 | 11 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Cmax = Maximum plasma concentration Measured in nanograms per millilitre (ng/mL)
| ng/mL | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| Bioequivalence Based on Cmax | 1060.8 ± 366.6 | 1743.3 ± 470.1 |
AUCT = Area under the concentration-time curve from 0 to the time of the last quantifiable concentration
| ng*h/mL | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| Bioequivalence Based on AUCT | 29180.6 ± 10557.1 | 36002.4 ± 9636.4 |
AUC∞ = Area under the concentration-time curve extrapolated to infinity
| ng*h/mL | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| Bioequivalence Based on AUC∞ | 30913.7 ± 11904.8 | 37273.4 ± 10738.5 |
| hours | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| Time of Maximum Measured Plasma Concentration (Tmax) | 6.00 (1.05 to 24.00) | 9.50 (0.33 to 21.00) |
The elimination half-life (T½el) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.
| Hours | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| Apparent Terminal Elimination Half-Life [T½el] | 14.37 ± 4.31 | 12.16 ± 3.51 |
| ng*h/mL | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| Area Under the Concentration-time Curve From 0 to 24 Hours [AUC0-24] | 16885.8 ± 5453.0 | 22512.8 ± 5045.2 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trazodone Contramid® OAD | — | 0/23 (0%) | 20/23 (87%) |
| Desyrel® | — | 0/22 (0%) | 21/22 (95.5%) |
| Event | Trazodone Contramid® OAD | Desyrel® |
|---|---|---|
| SomnolenceNervous system disorders | 17/23 | 20/22 |
| DizzinessNervous system disorders | 2/23 | 9/22 |
| NauseaGastrointestinal disorders | 2/23 | 6/22 |
| FatigueGeneral disorders | 6/23 | 4/22 |
| HeadacheNervous system disorders | 5/23 | 3/22 |
| Dry mouthGastrointestinal disorders | 2/23 | 3/22 |
| PalpitationsCardiac disorders | 0/23 | 2/22 |
| Dry eyesEye disorders | 1/23 | 2/22 |
| Ocular hyperaemiaEye disorders | 0/23 | 2/22 |
| DyspepsiaGastrointestinal disorders | 0/23 | 2/22 |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 0 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 35 ± 6 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 14 |
| Male | 10 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| Canada | 24 |
The record gives a start of Feb 2009, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Labopharm Inc.